Cortexa
Data updated
Enterprise Intelligence
Quarterly psychedelic drug-development briefing
Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.
Cortexa is a Melbourne-based psychedelic-medicines supplier, formed as a 50/50 joint venture between PharmAla Biotech and Vitura Health. It was the first company in the world to supply psilocybin under Australia's TGA Authorised Prescriber Scheme (2024) and is positioned as the only Australian company able to supply both GMP MDMA and psilocybin for clinical trials and prescriptions under the country's regulated prescribing pathways.
Manufacturing Snapshot
Psychedelic-Focused ManufacturerScope & Capabilities
Supply Use Cases
GxP / Compliance
Facilities & Access
Melbourne-based operational footprint for Australian market supply, with local manufacturing partnerships and distribution channels.
Manufacturing DetailsSupported Substances
Cortexa communications describe GMP psilocybin supply under the Australian Authorized Prescriber pathway and domestic GMP MDMA manufacturing scale-up.
Manufacturing Sources
Cortexa (Australia)
https://www.cortexa.com.au/
Cortexa First Supply of Psilocybin Under TGA Authorized Prescriber Scheme
https://pharmala.ca/media/2024/03/cortexa-leads-the-world-in-first-supply-of-psilocybin-under-the-tgas-authorized-prescriber-scheme
Cortexa Commences Manufacturing GMP LaNeo MDMA in Australia
https://pharmala.ca/media/2024/04/cortexa-commences-manufacturing-gmp-laneo-mdma-in-australia
Quick Facts
- HQ
- Australia
- Website
- Visit